Top Ten ICD-10 Tips for Oncology Practices

Slideshow

In the long term, ICD-10 has the potential to benefit oncology through improved data collection, but right now, practices just need to focus on preparing for the change. Here are 10 tips for oncologists.

Recent Videos
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
4 experts in this video
4 experts in this video
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
7 experts are featured in this series.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
Related Content
Investigators are actively enrolling patients with locally advanced rectal cancer in the phase 1b FORTRESS trial evaluating NG-350A plus chemotherapy.

FDA Grants Fast Track Designation to NG-350A For pMMR Rectal Cancer

Roman Fabbricatore
October 15th 2025
Article

Investigators are actively enrolling patients with locally advanced rectal cancer in the phase 1b FORTRESS trial evaluating NG-350A plus chemotherapy.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

The full indication excludes patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.

Ficerafusp Alfa/Pembrolizumab Receives FDA BTD in Front-Line HNSCC

Tim Cortese
October 14th 2025
Article

A median OS of 21.3 months was found in the phase 1/1b trial evaluating ficerafusp alfa plus pembrolizumab in those with metastatic and recurrent HNSCC.

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

Brooke Adams, PharmD, BCOP;Natalie Brumwell, PharmD, BCOP;Bryant A. Clemons, PharmD, BCOP
October 6th 2025
Podcast

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.

Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer

Roman Fabbricatore
October 14th 2025
Article

The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.

The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with P53 abnormal endometrial cancer.

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer

Roman Fabbricatore
October 13th 2025
Article

The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with P53 abnormal endometrial cancer.